Venatorx Pharmaceuticals Awarded BARDA Project BioShield Contract
Total award of up to $318M for development and procurement of novel antibiotic cefepime-taniborbactam for the treatment of melioidosis and multi-drug resistant infections
News
Relmada Therapeutics Announces Completion of Treatment in Company’s Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder
Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy
– Acquisition further strengthens Rocket’s leadership in AAV-based cardiac gene therapy and expands Company’s near-term clinical assets for the treatment of heart conditions
– Significant unmet medical need in BAG3-associated dilated cardiomyopathy, with meaningful commercial opportunity, comparable to Danon Disease
– Creates strong synergies by combining key assets, personnel, capabilities and IP, as well as access to world-leading scientific and clinical collaborators, expected to deliver long-term value for Rocket and Renovacor shareholders
– We believe compelling preclinical data generated by Renovacor validates mechanism of action of AAV-based transgene replacement strategy for BAG-3 dilated cardiomyopathy
– Expected to add approximately $38M in projected cash at closing; combined with recent $26M ATM sale, extends cash runway into 2Q’24
– Webcast to be held at 8:00 a.m. E.T. today, Sept. 20
Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington’s Disease and Prion Diseases
Innervace Secures Up to $40 Million to Advance Novel Regenerative Medicine Platform for Neurological Disorders
Series A financing round, led by Deerfield Management, to accelerate a new cell therapy modality for the treatment of neurological disorders, including Parkinson’s Disease
Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s Disease
Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer
– The study demonstrates the importance of tumor and lymph node-derived B cells for the discovery of antibodies directed at potentially novel targets
– The study results provide a framework for understanding the evolution of B cell families in cancer patients
Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
InfraScan Inc. Announces Publication of the Largest Study to date for TBI Diagnosis Utilizing NIRD
Duke Global Neurosurgery and Neurology publishes its independent results from the largest U.S.-based study using a near-infrared device (NIRD) to detect hemorrhage due to Traumatic Brain Injuries (TBI).